Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IVA | US
-0.68
-14.26%
Healthcare
Biotechnology
31/03/2024
02/06/2026
4.09
4.65
4.67
3.81
Inventiva S.A. a clinical-stage biopharmaceutical company focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix France.
View LessLow Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High Current Volume and Negative 1-Day Return
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
83.9%1 month
76.2%3 months
61.8%6 months
62.5%-
-
2.10
-1.15
0.54
-1.34
5.65
-
-98.36M
215.75M
215.75M
-
-1.91K
-
-58.70
-1.64K
14.15
0.46
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.66
Range1M
2.25
Range3M
2.98
Rel. volume
7.26
Price X volume
10.58M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Anavex Life Sciences Corp | AVXL | Biotechnology | 2.785 | 236.16M | -6.54% | n/a | 0.00% |
| Editas Medicine Inc | EDIT | Biotechnology | 2.82 | 232.58M | -15.57% | n/a | 16.68% |
| Shattuck Labs Inc | STTK | Biotechnology | 4.87 | 232.43M | -13.81% | n/a | 3.45% |
| Immix Biopharma Inc. | IMMX | Biotechnology | 8.365 | 229.62M | -9.27% | n/a | 4.57% |
| MONOPAR THERAPEUTICS | MNPR | Biotechnology | 61.26 | 215.66M | -4.88% | n/a | 0.00% |
| Anika Therapeutics Inc | ANIK | Biotechnology | 14.38 | 212.78M | -1.71% | n/a | 13.35% |
| LRMR | LRMR | Biotechnology | 3.3 | 210.56M | -5.98% | n/a | 2.65% |
| Caribou Biosciences Inc. | CRBU | Biotechnology | 2.32 | 209.64M | -4.53% | n/a | 8.80% |
| Arcturus Therapeutics Ltd | ARCT | Biotechnology | 7.65 | 206.87M | -1.54% | n/a | 11.94% |
| Nkarta Inc | NKTX | Biotechnology | 2.91 | 205.33M | -7.32% | n/a | 18.88% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CPI Card Group Inc | PMTS | Building Products & Equipment | 16.74 | 186.78M | -0.42% | 15.61 | -621.78% |
| ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 11.36 | 182.41M | 2.53% | n/a | 286.96% |
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 40.57 | 116.51M | -0.44% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.01 | 97.90M | 0.84% | 9.09 | 39.79% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 7.09 | 67.49M | 2.75% | n/a | 19.98% |
| ILAG | ILAG | Building Products & Equipment | 3.6016 | 65.04M | -4.21% | n/a | 5.48% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 9.37 | 58.67M | -0.64% | 14.48 | 7.10% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 19.59 | 29.83M | 25.34% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.11 | 16.22M | -2.63% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.4275 | 8.26M | -0.47% | n/a | 58.43% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.34 | 0.53 | Cheaper |
| Ent. to Revenue | 5.65 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.10 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 61.79 | 72.80 | Par |
| Debt to Equity | -1.15 | -1.23 | Cheaper |
| Debt to Assets | 0.54 | 0.25 | Expensive |
| Market Cap | 215.75M | 3.66B | Emerging |